Our location in the heart of San Diego’s thriving life sciences community means our team is made up of industry-leading experts in a range of disciplines and from a variety of backgrounds, united by a shared passion for turning science into meaningful discoveries for cancer patients.
The power to stop cancer.
The experience to know how.
The dedication to make a difference.
Radiopharmaceuticals – a class of precision oncology medicines – are poised to transform the treatment of solid tumors. By hitching a radioisotope to a small molecule, these potent therapies can selectively deliver the proven power of radiation directly to tumors throughout the body.
We are applying our deep drug discovery and development expertise against novel cancer targets from a broad class of surface receptors to produce targeted small molecule radiopharmaceuticals. We seek to create effective new treatments for cancer patients that enable us to go far beyond what’s been done before – bringing us closer to the day we can say “cure.”
Dual purpose enabling a targeted medicine approach
Part of a treatment strategy known as theragnostics, radiopharmaceuticals can be used for both therapy and diagnosis.
Radiopharmaceuticals, when tethering a radionuclide suitable for imaging, create a map of cancerous tumors in the body that provides precise diagnostic information. From the imaging results, the patients who are most likely to respond are identified and treated with individualized regiments of the therapeutic version of the same radiopharmaceutical. This precision medicine approach seeks to make substantial improvements in clinical outcomes.
Small molecules, tethered with powerful radioisotopes, are designed to exquisitely bind to receptors overexpressed in cancer and deliver powerful radiation to kill tumors, without affecting normal tissue.
Our unique approach marries a vast knowledge of GPCR biology with unrivaled proficiency in small molecule medicinal chemistry to develop potent and highly selective radiopharmaceuticals. We take a fit-for-purpose approach, pinpointing the precise target and selecting the ideal small molecule ligand paired with the optimal radioisotope to achieve a therapeutic effect.
Novel targets for solid tumors
Study R8760-101 is a multi-center Phase 1 clinical trial evaluating the safety and dosimetry of 68Ga-R8760, a first-in-class small molecule radioligand imaging agent being developed for patients diagnosed with adrenocortical carcinoma. 68Ga-R8760 was discovered by Radionetics Oncology for identifying melanocortin 2 receptor (MC2R)-expressing adrenocortical cancer lesions to select patients who may benefit from MC2R-directed radioconjugate therapy.
Frazier Life Sciences
Paul Grayson serves as Chief Executive Officer. Prior to joining Radionetics, he has been focusing on company origination, platform validation, IND enablement, and large and small molecule CMC through clinical proof of concept across a broad range of technologies and applications as both a CEO and a Venture Partner over the past 25 years. He was most recently the President and CEO of Tentarix Biotherapeutics, an oncology company focused on multi-functional biologics. His previous experiences also include founding roles at BirdRock Bio (acquired by Skye Biosciences), Fate Therapeutics (NASDAQ: FATE), Senomyx (acquired by Firmenich), and Aurora Biosciences (acquired by Vertex Pharmaceuticals).